.jpg)
This morning, June 17, 2018, members of Pluristem’s management opened the trading to mark the announcement of positive results in a Phase II clinical study among Intermittent Claudication sufferers. Pluristem has developed innovative technology for growing placenta-based stem cells and for their use in treating a variety of conditions, such as inflammation, orthopedic injuries and hermatological disorders The leading product developed by the company is intended for the treatment of severe Intermittent Claudication in the lower limbs.
Pluristem is included in the biomed sector on the Tel-Aviv Stock Exchange (TASE). The biomed sector comprises 45 companies with a total market cap of NIS 22 billion. The company, which was established in 2001, listed on NASDAQ at the end of 2007 and performed a dual listing on TASE in December 2010. The company has a market of NIS 500 million and is included in the TA-SME60 Index, the TA Tech-Elite Index and other high-tech indices.
Yaki Yanay, Pluristem’s President and Co-CEO: “We are extremely proud to be opening the weekly trading on TASE. The results of the study for the treatment of Peripheral Artery Disease that we presented last week bring important news for millions of patients around the world and represent a real hope for a remedy. We are pleased to see that the study results provide substantive validation that supports our clinical activity and shows that therapies using the product developed by us reduces the risk of surgical procedures, significantly improves the patient’s condition and, moreover, could lead to economic savings in the health systems and for regulators throughout the world.
We are getting an enthusiastic response from doctors who are seeing a statistically significant therapeutic effect in the study results, which could provide an answer to an important medical challenge and give indications that Pluristem’s cells could be the answer for both patients and doctors seeking effective medical solutions. Our results strengthen and contribute to the building of an Israeli biotechnology industry and testify to the potential inherent in such an industry, which is leading the way in groundbreaking technological developments at the spearhead of the medical world.”
Kobi Avramov, Head of TASE Research Unit: “We congratulate Pluristem, a company at the spearhead of Israeli biomed innovation, on another successful clinical study on the way to a medical solution that will make a significant improvement to the lives of many Intermittent Claudication sufferers. Since the completion of its dual listing, the company has been assisted by the capital market in raising considerable equity both overseas and in Israel. 40% of the total trade turnover in the company’s share takes place on TASE. Pluristem was one of the first companies to join the biomed and technology analyses program initiated by TASE, which 25 companies are now surveyed. The effectiveness of the analyses project for its participant companies is clear – growth in trading turnover both on TASE and on NASDAQ, growth in investments from institutional investors, and exposure to thousands of investors in Israel and overseas.”
Pictured from right to left: Kobi Avramov, Head of TASE Research Unit; Dr. Dan Peres, VP Clinical & Medical Matters; Erez Egozi, CFO; Boaz Leshem, VP Operations & Manufacturing; Orly Amiran, VP Quality Assurance; Zami Aberman, Chairman and Co-CEO; Racheli Ofir, VP Research & Intellectual Property; Yaky Yanay, President and Co-CEO; Efrat Livne-Hadass, VP Human Resources; and, Lior Raviv, VP Development.
Photo credit: Guy Assiag, for no financial consideration. 
